0
0.5
1
1.5
2+
Hospitalization
25%
Improvement
Relative Risk
Hospitalization, 7000mg..
52%
Hospitalization, 700mg, d..
-1%
Time to symptom improv..
-14%
primary
Time to symptom im.. (b)
-17%
primary
Progression, 7000mg
-1%
Progression, 700mg
2%
Viral load, 7000mg, day 3
26%
Viral load, 700mg, day 3
35%
Bamlanivimab/e.. ACTIV-2/A5401 LATE TREATMENT RCT
Is late treatment with bamlanivimab/etesevimab beneficial for COVID-19?
RCT 317 patients in the USA (August - November 2020)
Improved viral clearance with bamlanivimab/etesevimab (p=0.002)
c19early.org
Chew et al., Nature Communications, Aug 2022
Favors bamlanivimab/e..
Favors control